Marina Biotech Inc ausgebombter Nasdaq Wert vor Kursexplosion ?? - 500 Beiträge pro Seite
eröffnet am 07.12.11 13:27:57 von
neuester Beitrag 27.12.11 14:27:08 von
neuester Beitrag 27.12.11 14:27:08 von
Beiträge: 8
ID: 1.170.900
ID: 1.170.900
Aufrufe heute: 0
Gesamt: 863
Gesamt: 863
Aktive User: 0
ISIN: US00687E4061 · WKN: A3DWU1 · Symbol: ATRX
0,0060
USD
0,00 %
0,0000 USD
Letzter Kurs 02:10:00 Nasdaq OTC
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 38,27 | +28,16 | |
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 3,6100 | +17,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Feedback
Hallo zusammen,
denke das bei diesem ausgebombten Wert in den nächsten Wochen enormes Potential besteht. Wäre schön wenn hier eine rege Beteiligung stattfinden würde.
Gruß zuzlhuba
hier mal die letzten News
http://phx.corporate-ir.net/phoenix.zhtml?c=83674&p=irol-new…
denke das bei diesem ausgebombten Wert in den nächsten Wochen enormes Potential besteht. Wäre schön wenn hier eine rege Beteiligung stattfinden würde.
Gruß zuzlhuba
hier mal die letzten News
http://phx.corporate-ir.net/phoenix.zhtml?c=83674&p=irol-new…
Marina Biotech receives Chinese patent for Insulin Delivery Formulations
18 November 2011
Marina Biotech has received patent rights from the State Intellectual Property Office of the People's Republic of China (PRC) for its intranasal delivery of insulin.
The formulation is used to treat diseases associated with inappropriate insulin levels.
Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of the formulation.
Insulin is delivered to the nasal mucosa and does not enter the lungs.
The move is believed to strengthen the insulin patent portfolio in China.
18 November 2011
Marina Biotech has received patent rights from the State Intellectual Property Office of the People's Republic of China (PRC) for its intranasal delivery of insulin.
The formulation is used to treat diseases associated with inappropriate insulin levels.
Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of the formulation.
Insulin is delivered to the nasal mucosa and does not enter the lungs.
The move is believed to strengthen the insulin patent portfolio in China.
Es gibt bereits einen aktiven thread zu MARINA BIOTECH.
Bitte diesen thread weiter benutzen:
http://www.wallstreet-online.de/diskussion/1167458-51-60/new…
Bitte diesen thread weiter benutzen:
http://www.wallstreet-online.de/diskussion/1167458-51-60/new…
Trading Spotlight
Marina Biotech Announces $5 Million Private Placement
Implements Reverse Stock Split to Support Financing
BOTHELL, WA -- (MARKET WIRE) -- 12/23/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it has entered into a $5 million private placement with Socius CG II, Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group, LLC, and that it filed an amendment to its certificate of incorporation to effect a 1-for-10 reverse split of its common stock as of 5:00 p.m. EST on December 22, 2011.
"In an extremely challenging economic environment, we are pleased to continue to have the necessary financial resources to advance our industry-leading science and technology," stated J. Michael French, President and CEO of Marina Biotech. "With this additional funding, we will continue to move CEQ508 rapidly through clinical development with the goal of advancing a treatment for patients with Familial Adenomatous Polyposis quickly to the market. We are also having significant success in the development of microRNA-based therapeutics via both systemic and oral delivery and we look forward to partnering our capabilities in this area. Additionally, the reverse stock split, approved by the shareholders at our annual meeting in July, provides the Company with the authorized shares necessary to complete the placement and to execute potential future transactions with Socius or other partners as well as M&A opportunities."
Under the terms of the Securities Purchase Agreement, the Company has the right, in its sole discretion, over a term of two (2) years and subject to certain closing conditions and limitations, to sell to Socius up to a total of $5 million of redeemable Series B Preferred Stock of the Company (the "Preferred Stock"). The Preferred Stock will accrue a 10% dividend per annum from the date of issuance. Pursuant to the Securities Purchase Agreement, in addition to the Preferred Stock, Socius shall receive an Additional Investment Right and a Warrant, each to purchase shares of the Company's common stock.
When Preferred Stock is sold, Socius is obligated to exercise the Additional Investment Right and purchase a number of shares of common stock equal in dollar amount to 100% of the amount of Preferred Stock purchased at a per share price equal to the closing bid price of the common stock on the most recently completed trading day prior to the time that notice was delivered. Additionally, Socius is obligated to exercise a portion of the Warrant equal to a number of shares calculated by dividing (1) 35% of the dollar amount of Preferred Stock purchased by (2) the closing bid price of the common stock for the most recently completed trading day prior to the delivery of the notice.
Upon exercise, Socius must pay for the shares underlying the Additional Investment Right and the Warrant, at its option, either in cash or by delivering a full-recourse secured promissory note. Any such promissory note will bear interest at 2.0% per year calculated on a simple interest basis and be secured by securities (other than certain securities of the Company) owned by Socius with a fair market value equal to the principal amount of the promissory note.
The Company may redeem the Preferred Stock at any time and, at the option of either the Company or Socius, all outstanding promissory notes may be offset, exchanged and cancelled for all outstanding shares of Preferred Stock then held by Socius. The Preferred Stock is not convertible into shares of common stock and neither the Additional Investment Right nor the Warrant will be listed on any national securities exchange.
In order to facilitate the private placement, the Company filed an amendment to its certificate of incorporation to effect the 1-for-10 reverse split of its common stock. Marina Biotech's common stock will continue trading on the NASDAQ Global Market under the ticker symbol "MRNA", although the letter "D" will be temporarily appended to the ticker symbol for twenty trading days following the reverse split. The common stock will begin trading on a split-adjusted basis at the open of trading on Friday, December 23, 2011.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
Implements Reverse Stock Split to Support Financing
BOTHELL, WA -- (MARKET WIRE) -- 12/23/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it has entered into a $5 million private placement with Socius CG II, Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group, LLC, and that it filed an amendment to its certificate of incorporation to effect a 1-for-10 reverse split of its common stock as of 5:00 p.m. EST on December 22, 2011.
"In an extremely challenging economic environment, we are pleased to continue to have the necessary financial resources to advance our industry-leading science and technology," stated J. Michael French, President and CEO of Marina Biotech. "With this additional funding, we will continue to move CEQ508 rapidly through clinical development with the goal of advancing a treatment for patients with Familial Adenomatous Polyposis quickly to the market. We are also having significant success in the development of microRNA-based therapeutics via both systemic and oral delivery and we look forward to partnering our capabilities in this area. Additionally, the reverse stock split, approved by the shareholders at our annual meeting in July, provides the Company with the authorized shares necessary to complete the placement and to execute potential future transactions with Socius or other partners as well as M&A opportunities."
Under the terms of the Securities Purchase Agreement, the Company has the right, in its sole discretion, over a term of two (2) years and subject to certain closing conditions and limitations, to sell to Socius up to a total of $5 million of redeemable Series B Preferred Stock of the Company (the "Preferred Stock"). The Preferred Stock will accrue a 10% dividend per annum from the date of issuance. Pursuant to the Securities Purchase Agreement, in addition to the Preferred Stock, Socius shall receive an Additional Investment Right and a Warrant, each to purchase shares of the Company's common stock.
When Preferred Stock is sold, Socius is obligated to exercise the Additional Investment Right and purchase a number of shares of common stock equal in dollar amount to 100% of the amount of Preferred Stock purchased at a per share price equal to the closing bid price of the common stock on the most recently completed trading day prior to the time that notice was delivered. Additionally, Socius is obligated to exercise a portion of the Warrant equal to a number of shares calculated by dividing (1) 35% of the dollar amount of Preferred Stock purchased by (2) the closing bid price of the common stock for the most recently completed trading day prior to the delivery of the notice.
Upon exercise, Socius must pay for the shares underlying the Additional Investment Right and the Warrant, at its option, either in cash or by delivering a full-recourse secured promissory note. Any such promissory note will bear interest at 2.0% per year calculated on a simple interest basis and be secured by securities (other than certain securities of the Company) owned by Socius with a fair market value equal to the principal amount of the promissory note.
The Company may redeem the Preferred Stock at any time and, at the option of either the Company or Socius, all outstanding promissory notes may be offset, exchanged and cancelled for all outstanding shares of Preferred Stock then held by Socius. The Preferred Stock is not convertible into shares of common stock and neither the Additional Investment Right nor the Warrant will be listed on any national securities exchange.
In order to facilitate the private placement, the Company filed an amendment to its certificate of incorporation to effect the 1-for-10 reverse split of its common stock. Marina Biotech's common stock will continue trading on the NASDAQ Global Market under the ticker symbol "MRNA", although the letter "D" will be temporarily appended to the ticker symbol for twenty trading days following the reverse split. The common stock will begin trading on a split-adjusted basis at the open of trading on Friday, December 23, 2011.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
Marina Biotech and Mirna Therapeutics Announce License Agreement for the Development of microRNA-Based Therapeutics
Mirna Therapeutics Will Develop Oncology-Focused Compounds Utilizing Their Proprietary microRNAs Combined With Marina Biotech's Novel SMARTICLES(R) Liposomal Delivery Technology
BOTHELL, WA and AUSTIN, TX -- (MARKET WIRE) -- 12/23/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have entered into a license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology. Mirna will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $63 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.
"Given the challenge of effectively delivering oligonucleotides to target tissues, we devoted considerable effort to identifying an optimal delivery technology that would allow for systemic administration of our potent miRNA tumor suppressors and which is already in clinical testing," said Paul Lammers, M.D., M.Sc., President and CEO of Mirna Therapeutics. "With the dramatic in vivo results achieved with our miRNA mimics, we believe the SMARTICLES technology solves the delivery challenge for us, and we are now looking forward to bringing our miRNA mimics into the clinic in the next 18 months as promising targeted cancer therapeutics."
"We are extremely pleased to have entered into this relationship with a company as well respected in the area of microRNA-based therapeutics as Mirna Therapeutics," stated J. Michael French, President and CEO of Marina Biotech. "We are excited to see the continued advancement of oligonucleotide-based therapeutics and to be able to provide a technology capable of effectively delivering, in this case, systemically administered miRNA mimetics. We look forward to the rapid advancement of Mirna Therapeutics' clinical pipeline and the opportunity to bring novel therapeutics to patients in need."
In a recent poster entitled "The Development of a miRNA-based Therapeutic Candidate for Hepatocellular Carcinoma," presented at the November, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA, Mirna scientists showed that mimics of five tumor suppressor miRNAs, including miR-34 and let-7, all significantly inhibited the growth of liver tumors compared to animals treated with formulated negative control miRNAs. The five miRNA mimics were complexed with Marina Biotech's SMARTICLES delivery formulation and injected into NOD/SCID mice with orthotopically grown Hep3B human liver cancer xenografts.
The companies will present their respective science and technologies at the upcoming Biotech Showcase™ 2012, January 9-11, 2012 at the Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, CA. Mirna Therapeutics will present on Monday, 9 January at 3:00 pm and Marina Biotech will present on Tuesday, 10 January at 2:30 pm.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
Mirna Therapeutics Will Develop Oncology-Focused Compounds Utilizing Their Proprietary microRNAs Combined With Marina Biotech's Novel SMARTICLES(R) Liposomal Delivery Technology
BOTHELL, WA and AUSTIN, TX -- (MARKET WIRE) -- 12/23/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have entered into a license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology. Mirna will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $63 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.
"Given the challenge of effectively delivering oligonucleotides to target tissues, we devoted considerable effort to identifying an optimal delivery technology that would allow for systemic administration of our potent miRNA tumor suppressors and which is already in clinical testing," said Paul Lammers, M.D., M.Sc., President and CEO of Mirna Therapeutics. "With the dramatic in vivo results achieved with our miRNA mimics, we believe the SMARTICLES technology solves the delivery challenge for us, and we are now looking forward to bringing our miRNA mimics into the clinic in the next 18 months as promising targeted cancer therapeutics."
"We are extremely pleased to have entered into this relationship with a company as well respected in the area of microRNA-based therapeutics as Mirna Therapeutics," stated J. Michael French, President and CEO of Marina Biotech. "We are excited to see the continued advancement of oligonucleotide-based therapeutics and to be able to provide a technology capable of effectively delivering, in this case, systemically administered miRNA mimetics. We look forward to the rapid advancement of Mirna Therapeutics' clinical pipeline and the opportunity to bring novel therapeutics to patients in need."
In a recent poster entitled "The Development of a miRNA-based Therapeutic Candidate for Hepatocellular Carcinoma," presented at the November, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA, Mirna scientists showed that mimics of five tumor suppressor miRNAs, including miR-34 and let-7, all significantly inhibited the growth of liver tumors compared to animals treated with formulated negative control miRNAs. The five miRNA mimics were complexed with Marina Biotech's SMARTICLES delivery formulation and injected into NOD/SCID mice with orthotopically grown Hep3B human liver cancer xenografts.
The companies will present their respective science and technologies at the upcoming Biotech Showcase™ 2012, January 9-11, 2012 at the Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, CA. Mirna Therapeutics will present on Monday, 9 January at 3:00 pm and Marina Biotech will present on Tuesday, 10 January at 2:30 pm.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,57 | |
| +0,04 | |
| -6,82 | |
| 0,00 | |
| -0,20 | |
| 0,00 | |
| +2,78 | |
| -1,15 | |
| +5,36 | |
| - |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 76 | ||
| 61 | ||
| 60 | ||
| 36 | ||
| 28 | ||
| 27 | ||
| 17 | ||
| 15 | ||
| 13 | ||
| 12 |
